Evidence map›Paper›PMID 42246474›Full record

ArticleOncoimmunology2026

Local delivery of SBRT and IL-12 to murine PDAC tumors modulates hematopoiesis.

Tara G Vrooman, Emily R Quarato, Gary Hannon, Noah A Salama, Maggie L Lesch, Angela L Hughson, Vedika S Chandak, Nataliia Vdovichenko, Zhiming Jin, Ronald Lakony and 10 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Oncoimmunology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Tara G VroomanDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Emily R QuaratoWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Gary HannonDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.ORCID 0000-0003-1204-0299
Noah A SalamaWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Maggie L LeschDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Angela L HughsonDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Vedika S ChandakDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Nataliia VdovichenkoWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Zhiming JinWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Ronald LakonyWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Jian YeDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Sarah L EcklDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Sidney LesserDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Edith M LordCenter for Tumor Immunology Research, University of Rochester Medical Center, Rochester, NY, USA.
David C LinehanDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.
Haoming QiuDepartment of Radiation Oncology, University of Rochester Medical Center, Rochester, NY, USA.
Nadia LuheshiOncology R&D, AstraZeneca, The Discovery Center, Cambridge Biomedical Campus, Cambridge, UK.
Jim EylesOncology R&D, AstraZeneca, The Discovery Center, Cambridge Biomedical Campus, Cambridge, UK.
Laura M CalviWilmot Cancer Institute, University of Rochester Medical Center, Rochester, NY, USA.
Scott A GerberDepartment of Surgery, University of Rochester Medical Center, Rochester, NY, USA.

Funding

The T32 Predoctoral Training Program in Immunology (PTPI)T32AI007285 · NIAID · UNIVERSITY OF ROCHESTER · PI Scott Andrew Gerber, JACQUES Robert · 1986 to 2026
$7.6M
Repolarizing the Tumor and Metastatic Microenvironments to Treat Patients with Pancreatic CancerR01CA262580 · NCI · UNIVERSITY OF ROCHESTER · PI GERBER, SCOTT ANDREW, LINEHAN, DAVID C · 2021 to 2025
$1.6M
Targeting Intrinsic and Extrinsic Barriers to Treat Metastatic Pancreatic CancerR01CA295861 · NCI · UNIVERSITY OF ROCHESTER · PI Darren Richard Carpizo, Scott Andrew Gerber · 2025 to 2026
$1.3M
NCI NIH HHS R01 CA262580NCI NIH HHS R01 CA295861NIAID NIH HHS T32 AI007285
6 · The paper itself

Abstract

Standard of care radiotherapy and chemotherapy have shown limited efficacy in pancreatic ductal adenocarcinoma (PDAC). Immunotherapy has emerged as a promising treatment but has been hindered by systemic toxicities. A shift from systemic to localized delivery has reduced adverse effects and improved response rates in various cancers. However, the impact of tumor-targeted therapies on distant tissues, such as the bone marrow, remains underexplored. In a murine model of PDAC, we treated tumors with targeted stereotactic body radiation therapy (SBRT) and intratumoral interleukin-12 mRNA (IL-12). We evaluated tumor, blood, and bone marrow cells for therapy-induced changes over a period of 13 d to 13 months. Our results showed that while SBRT/IL-12 locally eradicated primary tumors, it also induced significant effects in the bone marrow. Early effects included acute lymphopenia in the blood and an immunostimulatory response in the bone marrow, leading to increased hematopoiesis. Long-term effects involved a reduction in hematopoietic stem cells (HSCs) and a shift towards a myeloid lineage, suggesting potential premature aging of the HSC population. These findings highlight the profound impact of localized SBRT/IL-12 therapy on distal bone marrow, emphasizing the need for further investigation into the long-term immunological consequences of localized cancer treatments.

Indexed as

Carcinoma, Pancreatic DuctalHematopoiesisInterleukin-12Pancreatic NeoplasmsRadiosurgeryAnimalsBone MarrowCell Line, TumorDisease Models, AnimalFemaleHematopoietic Stem CellsMiceMice, Inbred C57BLInterleukin-12hematopoiesishematopoietic stem cellsinterleukin-12, bone marrowPancreatic ductal adenocarcinomastereotactic body radiation therapy

Identifiers

PMID42246474
PMCPMC13245092

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.